Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 64
Filter
1.
J Dermatolog Treat ; 35(1): 2353693, 2024 Dec.
Article in English | MEDLINE | ID: mdl-38862417

ABSTRACT

Purpose: There is limited information about the diagnosis and treatment of hidradenitis suppurativa (HS) in the Kingdom of Saudi Arabia (KSA). This Delphi consensus study was conducted to develop recommendations for the management of HS in the KSA.Methods: The expert panel including 12 dermatologists with extensive experience treating HS patients provided nine consensus statements and recommendations on diagnosis and assessment, management, comorbidities and multidisciplinary approach, and education. The experts also developed clinical questions pertaining to the management of HS and rolled out as a survey to 119 dermatologists practising in the KSA.Results: The topics covered included: referring physicians' awareness of HS; referral criteria for HS; definition of moderate-to-severe HS; treatment goals; definition of treatment success; treatment and biologic initiation; comorbidities and multidisciplinary approach; patient education and awareness of HS. Full consensus (100%) from the expert dermatologists was received on all the topics except referring physicians' awareness of HS, definition of treatment success, and treatment and biologic initiation. The survey results resonated with the expert opinion.Conclusion: As HS is a chronic disease with negative impact on quality-of-life, timely diagnosis and treatment, early identification of comorbid conditions and a multidisciplinary care approach are crucial for effective management of HS.


Subject(s)
Consensus , Delphi Technique , Hidradenitis Suppurativa , Referral and Consultation , Hidradenitis Suppurativa/therapy , Hidradenitis Suppurativa/diagnosis , Humans , Saudi Arabia , Referral and Consultation/standards , Referral and Consultation/statistics & numerical data , Severity of Illness Index , Comorbidity , Dermatologists/standards , Dermatologists/statistics & numerical data , Quality of Life , Patient Education as Topic/standards , Treatment Outcome
3.
Article in English | MEDLINE | ID: mdl-34169702

ABSTRACT

Almost 13 months have passed since the World Health Organization (WHO) declared the coronavirus disease 19 (COVID-19) pandemic, caused by the SARS-CoV-2, on March 11th, 2020. During this period, we have realized that the most effective weapon we have to prevent SARS-CoV-2 infection, or to make it less aggressive, is vaccines. Currently, according to the WHO document "Draft landscape of COVID-19 candidate vaccines," there are 275 vaccines in development against the virus, although at the moment there are four preparations in distribution in the United States and in Europe. The characteristics of these vaccines are quite different from each other and may even be unfamiliar in the medical field. In particular, among dermatologists, knowledge of vaccines is of fundamental importance, especially in atopic dermatitis. Atopic patients are aware of having a predisposition to develop allergies, and so they are asking dermatologists about the safety of the vaccines currently available against the SARS-CoV-2. This article provides an up-to-date overview of this topic by reviewing current literature and sharing our personal experience.


Subject(s)
COVID-19 Vaccines/therapeutic use , COVID-19/prevention & control , Dermatitis, Atopic/etiology , Dermatologists/standards , Practice Patterns, Physicians'/standards , COVID-19 Vaccines/adverse effects , Clinical Competence , Dermatitis, Atopic/prevention & control , Europe , Humans
4.
Australas J Dermatol ; 62(3): 292-299, 2021 Aug.
Article in English | MEDLINE | ID: mdl-34117779

ABSTRACT

BACKGROUND/OBJECTIVES: Vulval lichen sclerosus (VLS) is a chronic inflammatory skin condition predominantly affecting the anogenital region in women and children. To date, there is lack of agreement amongst experts on a severity scale to aid assessment, research and treatment stratification on VLS. Furthermore, literature on best practice for long-term management of VLS is lacking. The aim of this consensus is to provide broad guidelines on the short and long-term management of VLS. METHODS: An initial focus group of Australasian experts in vulval dermatology developed a draft consensus statement for the management of VLS. Based on the results of the draft statement, a consensus panel of 22 Australasian experts, comprised of the initial and additional members, participated in an anonymous four-stage eDelphi process. Round 1 involved generation and voting on statements from the draft consensus statement developed by the focus group. In Rounds 2, 3 & 4, panel members were presented formal feedback from previous rounds and asked to indicate their level of agreement. Consensus was reached if there was ≥70% agreement on the importance of an item in the 4 (agree) to 5 (strongly agree) range. RESULTS: The expert panel, with a total of 504 collective years of experience in the field of VLS, reached consensus on a core set of 51 management statements related to diagnosis, severity, initial and long-term management, follow-up, and complications of VLS. CONCLUSIONS: This study has identified a set of management statements for VLS that may be useful in clinical practice in the Australasian population.


Subject(s)
Consensus , Lichen Sclerosus et Atrophicus/therapy , Practice Guidelines as Topic/standards , Practice Patterns, Physicians'/standards , Vulvar Lichen Sclerosus/therapy , Dermatologists/standards , Female , Humans , Lichen Sclerosus et Atrophicus/prevention & control , Vulvar Lichen Sclerosus/prevention & control
7.
JAMA Dermatol ; 157(2): 189-197, 2021 02 01.
Article in English | MEDLINE | ID: mdl-33404623

ABSTRACT

Importance: Dermoscopy education in US dermatology residency programs varies widely, and there is currently no existing expert consensus identifying what is most important for resident physicians to know. Objectives: To identify consensus-based learning constructs representing an appropriate foundational proficiency in dermoscopic image interpretation for dermatology resident physicians, including dermoscopic diagnoses, associated features, and representative teaching images. Defining these foundational proficiency learning constructs will facilitate further skill development in dermoscopic image interpretation to help residents achieve clinical proficiency. Design, Setting, and Participants: A 2-phase modified Delphi surveying technique was used to identify resident learning constructs in 3 sequential sets of surveys-diagnoses, features, and images. Expert panelists were recruited through an email distributed to the 32 members of the Pigmented Lesion Subcommittee of the Melanoma Prevention Working Group. Twenty-six (81%) opted to participate. Surveys were distributed using RedCAP software. Main Outcomes and Measures: Consensus on diagnoses, associated dermoscopic features, and representative teaching images reflective of a foundational proficiency in dermoscopic image interpretation for US dermatology resident physicians. Results: Twenty-six pigmented lesion and dermoscopy specialists completed 8 rounds of surveys, with 100% (26/26) response rate in all rounds. A final list of 32 diagnoses and 116 associated dermoscopic features was generated. Three hundred seventy-eight representative teaching images reached consensus with panelists. Conclusions and Relevance: Consensus achieved in this modified Delphi process identified common dermoscopic diagnoses, associated features, and representative teaching images reflective of a foundational proficiency in dermoscopic image interpretation for dermatology residency training. This list of validated objectives provides a consensus-based foundation of key learning points in dermoscopy to help resident physicians achieve clinical proficiency in dermoscopic image interpretation.


Subject(s)
Dermatologists/standards , Dermatology/methods , Dermoscopy/standards , Internship and Residency/standards , Clinical Competence , Delphi Technique , Dermatologists/education , Dermatology/education , Dermatology/standards , Dermoscopy/education , Humans , Skin Diseases/diagnosis , Surveys and Questionnaires
10.
Dermatol Surg ; 46(12): 1676-1682, 2020 12.
Article in English | MEDLINE | ID: mdl-33165083

ABSTRACT

BACKGROUND: Laser procedures are becoming more prevalent across multiple medical specialties for a variety of indications. The plumes created by these lasers have raised concern for the dissemination of an infectious material. OBJECTIVE: To review and summarize the information on viral dissemination in laser plumes available in the literature. MATERIALS AND METHODS: Data Sources A systematic review was performed on English and non-English articles using the PubMed and the Cochrane databases. A manual search of bibliographies from relevant articles was also performed to collect additional studies. STUDY SELECTION: Only articles in the English language with full texts available that pertained to viral particles in laser plumes were included. Data Extraction Two authors performed independent article selections using predefined inclusion and exclusion criteria. RESULTS: There have been case reports of possible transmission of human papillomavirus (HPV) by inhalation of laser-produced aerosols. Multiple investigators have attempted to recreate this scenario in the laboratory to qualify this risk. Others have conducted clinical experiments to determine the presence of HPV in laser plumes. CONCLUSION: The current body of the literature suggests that laser surgeons are at a risk for HPV exposure by inhalation of laser-derived aerosols. We offer best practice recommendations for laser operators.


Subject(s)
Aerosols/adverse effects , Laser Therapy/adverse effects , Occupational Diseases/prevention & control , Occupational Exposure/adverse effects , Papillomavirus Infections/transmission , Alphapapillomavirus/pathogenicity , Dermatologists/standards , Dermatologists/statistics & numerical data , Head and Neck Neoplasms/epidemiology , Head and Neck Neoplasms/prevention & control , Head and Neck Neoplasms/virology , Humans , Incidence , Inhalation Exposure/adverse effects , Inhalation Exposure/standards , Inhalation Exposure/statistics & numerical data , Laryngeal Diseases/epidemiology , Laryngeal Diseases/prevention & control , Laryngeal Diseases/virology , Laser Therapy/standards , Laser Therapy/statistics & numerical data , Masks/standards , Occupational Diseases/epidemiology , Occupational Diseases/virology , Occupational Exposure/statistics & numerical data , Papillomavirus Infections/epidemiology , Papillomavirus Infections/surgery , Papillomavirus Infections/virology , Practice Guidelines as Topic , Protective Clothing/standards , Skin/radiation effects , Skin/virology , Skin Neoplasms/surgery , Skin Neoplasms/virology , Squamous Cell Carcinoma of Head and Neck/epidemiology , Squamous Cell Carcinoma of Head and Neck/prevention & control , Squamous Cell Carcinoma of Head and Neck/virology , Surgeons/standards , Surgeons/statistics & numerical data
13.
J Med Internet Res ; 22(9): e18091, 2020 09 11.
Article in English | MEDLINE | ID: mdl-32915161

ABSTRACT

BACKGROUND: Early detection of melanoma can be lifesaving but this remains a challenge. Recent diagnostic studies have revealed the superiority of artificial intelligence (AI) in classifying dermoscopic images of melanoma and nevi, concluding that these algorithms should assist a dermatologist's diagnoses. OBJECTIVE: The aim of this study was to investigate whether AI support improves the accuracy and overall diagnostic performance of dermatologists in the dichotomous image-based discrimination between melanoma and nevus. METHODS: Twelve board-certified dermatologists were presented disjoint sets of 100 unique dermoscopic images of melanomas and nevi (total of 1200 unique images), and they had to classify the images based on personal experience alone (part I) and with the support of a trained convolutional neural network (CNN, part II). Additionally, dermatologists were asked to rate their confidence in their final decision for each image. RESULTS: While the mean specificity of the dermatologists based on personal experience alone remained almost unchanged (70.6% vs 72.4%; P=.54) with AI support, the mean sensitivity and mean accuracy increased significantly (59.4% vs 74.6%; P=.003 and 65.0% vs 73.6%; P=.002, respectively) with AI support. Out of the 10% (10/94; 95% CI 8.4%-11.8%) of cases where dermatologists were correct and AI was incorrect, dermatologists on average changed to the incorrect answer for 39% (4/10; 95% CI 23.2%-55.6%) of cases. When dermatologists were incorrect and AI was correct (25/94, 27%; 95% CI 24.0%-30.1%), dermatologists changed their answers to the correct answer for 46% (11/25; 95% CI 33.1%-58.4%) of cases. Additionally, the dermatologists' average confidence in their decisions increased when the CNN confirmed their decision and decreased when the CNN disagreed, even when the dermatologists were correct. Reported values are based on the mean of all participants. Whenever absolute values are shown, the denominator and numerator are approximations as every dermatologist ended up rating a varying number of images due to a quality control step. CONCLUSIONS: The findings of our study show that AI support can improve the overall accuracy of the dermatologists in the dichotomous image-based discrimination between melanoma and nevus. This supports the argument for AI-based tools to aid clinicians in skin lesion classification and provides a rationale for studies of such classifiers in real-life settings, wherein clinicians can integrate additional information such as patient age and medical history into their decisions.


Subject(s)
Artificial Intelligence/standards , Dermatologists/standards , Dermoscopy/methods , Diagnostic Imaging/classification , Melanoma/diagnostic imaging , Skin Neoplasms/diagnostic imaging , Humans , Internet , Melanoma/diagnosis , Skin Neoplasms/diagnosis , Surveys and Questionnaires
14.
Am J Clin Dermatol ; 21(5): 725-732, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32803546

ABSTRACT

BACKGROUND: Eyebrow and eyelash hair loss and nail damage-in addition to scalp hair loss-are important signs/symptoms of alopecia areata (AA) to patients and deserve assessment in AA clinical trials. OBJECTIVES: Our objective was to develop clinician-reported outcome (ClinRO) and patient-reported outcome (PRO) measures and accompanying photoguides to aid in the assessment of AA-related eyebrow, eyelash and nail signs/symptoms. METHODS: Iterative rounds of qualitative, semi-structured interviews were conducted with US expert dermatologists and North American patients with AA. Patients with eyebrow, eyelash and nail involvement were purposefully sampled. Interview transcripts were qualitatively analyzed. RESULTS: Dermatologists (n = 10) described eyebrow and eyelash loss as concerning for affected patients and, along with nail appearance, as deserving assessment. Dermatologist data informed the development of single item, 4-point Likert-type ClinRO and PRO measures of current eyebrow loss, eyelash loss and nail appearance and a PRO measure of eye irritation. Patients (n = 45, age 15-72 years) confirmed the importance and relevance of these signs/symptoms. Interim revision resulted in measures that were understood by and relevant to patients. Dermatologists (n = 5) and patients (n = 10, age 21-54 years) participated in the development of the eyebrow, eyelash and nail photoguides and confirmed that they included photos that appropriately represented different severity levels and were helpful to derive and standardize ratings across raters. CONCLUSIONS: The ClinRO and PRO measures for eyebrow, eyelash and nail appearance, with their accompanying photoguides and the PRO Measure for Eye Irritation provide clear and meaningful assessments of outcomes important to patients with AA.


Subject(s)
Alopecia Areata/diagnosis , Eyebrows/diagnostic imaging , Eyelashes/diagnostic imaging , Nails/diagnostic imaging , Patient Reported Outcome Measures , Adolescent , Adult , Aged , Alopecia Areata/therapy , Clinical Trials as Topic , Cross-Sectional Studies , Dermatologists/standards , Female , Humans , Male , Middle Aged , Photography/standards , Practice Guidelines as Topic , Qualitative Research , Treatment Outcome , Young Adult
16.
J Am Acad Dermatol ; 83(4): 1150-1159, 2020 Oct.
Article in English | MEDLINE | ID: mdl-32569797

ABSTRACT

Dermatologists treating immune-mediated skin disease must now contend with the uncertainties associated with immunosuppressive use in the context of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic. Although the risk of infection with many commonly used immunosuppressive agents remains low, direct data evaluating the safety of such agents in coronavirus disease 2019 (COVID-19) are scarce. This article reviews and offers guidance based on currently available safety data and the most recent COVID-19 outcome data in patients with immune-mediated dermatologic disease. The interdisciplinary panel of experts emphasizes a stepwise, shared decision-making approach in the management of immunosuppressive therapy. The goal of this article is to help providers minimize the risk of disease flares while simultaneously minimizing the risk of iatrogenic harm during an evolving pandemic.


Subject(s)
Coronavirus Infections/prevention & control , Dermatology/standards , Immunosuppression Therapy/standards , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Practice Guidelines as Topic , Skin Diseases/therapy , Advisory Committees/standards , Betacoronavirus/immunology , Betacoronavirus/pathogenicity , COVID-19 , Clinical Decision-Making , Coronavirus Infections/epidemiology , Coronavirus Infections/immunology , Coronavirus Infections/virology , Decision Making, Shared , Dermatologists/standards , Dermatology/methods , Disease Susceptibility/immunology , Hospitalists/standards , Humans , Immunosuppression Therapy/adverse effects , Immunosuppression Therapy/methods , Interdisciplinary Communication , Pneumonia, Viral/epidemiology , Pneumonia, Viral/immunology , Pneumonia, Viral/virology , SARS-CoV-2 , Skin Diseases/immunology , Societies, Medical/standards , Symptom Flare Up
18.
J Cosmet Dermatol ; 19(8): 1822-1825, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32460391

ABSTRACT

BACKGROUND: Severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2; COVID-19), which causes coronavirus disease 2019, is highly contagious and a particularly popular problem in all around the world and also in all departments of every hospital. AIMS: Protecting the well-being of the aesthetic dermatologists while providing a sufficient workforce is vital for pandemic planning. RESULTS AND CONCLUSIONS: In this article, we will discuss this problem from an aesthetic dermatology aspect and we will review whether these procedures are safe or not.


Subject(s)
Betacoronavirus/pathogenicity , Coronavirus Infections/prevention & control , Cosmetic Techniques , Dermatology/organization & administration , Infection Control/organization & administration , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Anti-Infective Agents, Local/administration & dosage , Anti-Infective Agents, Local/standards , COVID-19 , Congresses as Topic/standards , Coronavirus Infections/epidemiology , Coronavirus Infections/transmission , Coronavirus Infections/virology , Dermatologists/organization & administration , Dermatologists/standards , Dermatology/education , Dermatology/standards , Education, Medical/organization & administration , Education, Medical/standards , Esthetics , Hand Hygiene/standards , Humans , Infection Control/instrumentation , Infection Control/standards , Infectious Disease Transmission, Patient-to-Professional/prevention & control , Infectious Disease Transmission, Professional-to-Patient/prevention & control , Personal Protective Equipment/standards , Pneumonia, Viral/epidemiology , Pneumonia, Viral/transmission , Pneumonia, Viral/virology , SARS-CoV-2 , Telemedicine/organization & administration , Telemedicine/standards
19.
J Am Acad Dermatol ; 83(3): 839-846, 2020 Sep.
Article in English | MEDLINE | ID: mdl-32344071

ABSTRACT

BACKGROUND: An Investigator Global Assessment (IGA) is recommended by health agencies for drug registration in atopic dermatitis (AD). Current IGA scales lack standardization. OBJECTIVES: To develop an IGA scale, training module, and clinical certification examination for use in AD trials; establish content validity; and assess reliability. METHODS: Expert dermatologists participated in the development of the validated IGA for AD (vIGA-ADTM). Reliability (interrater and intrarater) was assessed by 2 web-based surveys. Clinical certification for investigators consisted of a training module and examination. RESULTS: Expert consensus was achieved around a 5-point IGA scale including morphologic descriptions, and content validity was established. Survey 1 showed strong interrater reliability (Kendall's coefficient of concordance W [Kendall's W], 0.809; intraclass correlation [ICC], 0.817) and excellent agreement (weighted kappa, 0.857). Survey 2, completed 5 months after training of dermatologists, showed improvements in scale reliability (Kendall's W, 0.819; ICC, 0.852; weighted kappa, 0.889). In this study, 627 investigators completed vIGA-AD training and certification. LIMITATIONS: Ratings were assessed on photographs. CONCLUSION: A validated IGA scale and training module were developed with the intent of harmonizing assessment of disease severity in AD trials. Strong reliability and excellent agreement between assessments were observed.


Subject(s)
Consensus , Dermatitis, Atopic/diagnosis , Outcome Assessment, Health Care/standards , Severity of Illness Index , Adult , Child , Consensus Development Conferences as Topic , Dermatitis, Atopic/therapy , Dermatologists/standards , Dermatologists/statistics & numerical data , Humans , Observer Variation , Photography , Reproducibility of Results , Skin/diagnostic imaging , Surveys and Questionnaires/statistics & numerical data , Telecommunications
20.
J Cancer Educ ; 35(4): 819-825, 2020 08.
Article in English | MEDLINE | ID: mdl-32193871

ABSTRACT

The early diagnosis of cutaneous melanoma provides less aggressive treatment reducing mortality. General practitioners are responsible for cancer diagnoses in the Brazilian Public Health System and therefore play a crucial role in the prevention and early detection of melanoma. To assess the melanoma knowledge of a primary healthcare physician, the general practitioner, compared to a dermatologist. General practitioners and dermatologists answered a questionnaire about melanoma and the management of suspected cases. The results of both groups were compared. The sample consisted of 80 specialists and 160 general practitioners. When asked about the "ABCDE" rule, 96.2% of the dermatologists knew about it, compared to 34.4% of the general practitioners. The percentage of dermatologists who examined the whole skin of the patient at high risk for melanoma was 90% vs. 24.5% amongst general practitioners. The most cited reasons for the absence of the examination of patients at risk for melanoma were lack of time at the consultations (17.6% specialists, 66.1% generalists) and an excessive number of patients (17.6% specialists, 61.5% generalists). General practitioner has less knowledge about melanoma compared to the dermatologists and presents deficient behaviors about patients at risk or who have suspicious lesions, indicating the need for training and continuing education.


Subject(s)
Dermatologists/statistics & numerical data , Diagnostic Errors/statistics & numerical data , General Practitioners/statistics & numerical data , Health Knowledge, Attitudes, Practice , Melanoma/diagnosis , Practice Patterns, Physicians'/standards , Skin Neoplasms/diagnosis , Adult , Brazil/epidemiology , Cross-Sectional Studies , Dermatologists/standards , Female , General Practitioners/standards , Humans , Male , Melanoma/epidemiology , Skin Neoplasms/epidemiology , Surveys and Questionnaires , Melanoma, Cutaneous Malignant
SELECTION OF CITATIONS
SEARCH DETAIL
...